Royal Bank of Canada’s Ovid Therapeutics OVID Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7K | Buy |
3,310
+2,235
| +208% | +$4K | ﹤0.01% | 6331 |
|
|
2025
Q4 | $2K | Sell |
1,075
-3,509
| -77% | -$5.41K | ﹤0.01% | 6917 |
|
|
2025
Q3 | $6K | Sell |
4,584
-2,194
| -32% | -$1.9K | ﹤0.01% | 6659 |
|
|
2025
Q2 | $2K | Buy |
6,778
+1,004
| +17% | +$303 | ﹤0.01% | 6813 |
|
|
2025
Q1 | $1K | Buy |
5,774
+4,077
| +240% | +$2.51K | ﹤0.01% | 6695 |
|
|
2024
Q4 | $1K | Sell |
1,697
-3,465
| -67% | -$3.88K | ﹤0.01% | 6810 |
|
|
2024
Q3 | $6K | Sell |
5,162
-377
| -7% | -$394 | ﹤0.01% | 6465 |
|
|
2024
Q2 | $4K | Buy |
5,539
+3,283
| +146% | +$9.14K | ﹤0.01% | 6607 |
|
|
2024
Q1 | $7K | Sell |
2,256
-21,123
| -90% | -$70.7K | ﹤0.01% | 6346 |
|
|
2023
Q4 | $75K | Buy |
23,379
+10,560
| +82% | +$36.1K | ﹤0.01% | 5784 |
|
|
2023
Q3 | $49K | Buy |
12,819
+6,598
| +106% | +$23.7K | ﹤0.01% | 5794 |
|
|
2023
Q2 | $20K | Buy |
6,221
+6,164
| +10,814% | +$20.9K | ﹤0.01% | 6216 |
|
|
2023
Q1 | $0 | Buy |
57
+1
| +2% | +$2 | ﹤0.01% | 7357 |
|
|
2022
Q4 | $0 | Sell |
56
-403
| -88% | -$687 | ﹤0.01% | 7579 |
|
|
2022
Q3 | $1K | Buy |
+459
| New | +$960 | ﹤0.01% | 7235 |
|
|
2022
Q2 | – | Sell |
-960
| Closed | -$3K | – | 7615 |
|
|
2022
Q1 | $3K | Sell |
960
-540
| -36% | -$1.7K | ﹤0.01% | 7392 |
|
|
2021
Q4 | $5K | Sell |
1,500
-6,000
| -80% | -$20.6K | ﹤0.01% | 7225 |
|
|
2021
Q3 | $25K | Sell |
7,500
-17,221
| -70% | -$62.8K | ﹤0.01% | 6580 |
|
|
2021
Q2 | $97K | Sell |
24,721
-50,101
| -67% | -$198K | ﹤0.01% | 5633 |
|
|
2021
Q1 | $301K | Sell |
74,822
-7,479
| -9% | -$24.8K | ﹤0.01% | 4611 |
|
|
2020
Q4 | $190K | Sell |
82,301
-337,290
| -80% | -$1.57M | ﹤0.01% | 4892 |
|
|
2020
Q3 | $2.41M | Buy |
419,591
+299,101
| +248% | +$2M | ﹤0.01% | 2537 |
|
|
2020
Q2 | $888K | Buy |
120,490
+113,366
| +1,591% | +$530K | ﹤0.01% | 3278 |
|
|
2020
Q1 | $21K | Buy |
7,124
+454
| +7% | +$1.53K | ﹤0.01% | 5521 |
|
|
2019
Q4 | $28K | Buy |
6,670
+3,314
| +99% | +$10.5K | ﹤0.01% | 5714 |
|
|
2019
Q3 | $11K | Sell |
3,356
-799
| -19% | -$1.82K | ﹤0.01% | 5747 |
|
|
2019
Q2 | $8K | Buy |
4,155
+2,000
| +93% | +$3.57K | ﹤0.01% | 6112 |
|
|
2019
Q1 | $4K | Sell |
2,155
-54
| -2% | -$135 | ﹤0.01% | 6350 |
|
|
2018
Q4 | $5K | Sell |
2,209
-277
| -11% | -$1.26K | ﹤0.01% | 6166 |
|
|
2018
Q3 | $14K | Buy |
2,486
+544
| +28% | +$4.12K | ﹤0.01% | 5855 |
|
|
2018
Q2 | $16K | Sell |
1,942
-850
| -30% | -$7.3K | ﹤0.01% | 5646 |
|
|
2018
Q1 | $20K | Buy |
+2,792
| New | +$22.6K | ﹤0.01% | 5453 |
|
|
2017
Q4 | – | Sell |
-329
| Closed | -$3K | – | 6786 |
|
|
2017
Q3 | $3K | Buy |
329
+323
| +5,383% | +$2.69K | ﹤0.01% | 6519 |
|
|
2017
Q2 | $0 | Buy |
+6
| New | +$78 | ﹤0.01% | 6708 |
|
Other funds holding OVID
RCM
AAA
EAM
VCM
ACM
SVCM
Royal Bank of Canada's OVID Position: Q1 2026 in Review
Royal Bank of Canada increased its Ovid Therapeutics (OVID) stake by 208% in Q1 2026, buying an estimated $4K and bringing the position to 3,310 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #6331.
Royal Bank of Canada first reported a position in OVID in Q2 2017 and has held it in 34 quarters since. The position peaked at $2.41M in Q3 2020. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.
- Royal Bank of Canada held 3,310 shares of Ovid Therapeutics worth $7K as of Q1 2026.
- Royal Bank of Canada bought 2,235 Ovid Therapeutics shares in Q1 2026, an estimated $4K.
- Ovid Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6331 holding.
- Royal Bank of Canada first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 34 quarters since.
- Royal Bank of Canada's Ovid Therapeutics position peaked at $2.41M in Q3 2020.
- 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.